Wednesday, August 17, 2016 8:28:05 PM
What you are referring to was a post hoc analysis, a retrospective look if you will, that was not part of the original phase II monotherapy design. Patients weren't randomly selected to go on and test anti-pd-1 drug as part of the monotherapy il-12 trial.
The fact that the trial didn't use a TIL biomarker shouldn't negate the stellar post hoc clinical responses. Remember, the il-12 monotherapy achieved response rates that were better than anti-pd-1 or ctla-4 therapies. These patients who responded were not later evaluated in the post hoc analysis. Those who did not respond likely had a proportional increase in pd-1/ctla-4 positive TIL, but obviously those patients won't respond until the anti-pd-1 drug is introduced. And when patients did subsequently go on to an anti-pd-1 therapy, they responded at 75% with 50% complete remissions. Those percentages are completely unheard of in stage III and IV melanoma. Electroporated il-12 sure seems to be increasing the relative proportion of pd-1 positive TIL in tumor microenvironments. This is the necessary 'substrate' we keep hearing about. Without il-12, these advanced stage melanoma patients should only be achieving 20-30% response rates, with less than 10% complete remission.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM